Reena Gupta, MD
Ophthalmology · Brookline, MANPI 1144587544
Payments from drug & device makers
Across 318 payments — averaging $122.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$17K
- Rxsight Inc$5K
- Biotissue Holdings Inc.$4K
- Nidek CO., LTD.$3K
- Tarsus Pharmaceuticals, Inc.$2K
- Bausch & Lomb Americas Inc.$2K
- plus $6K from 20 others
What the payments were for
- Consulting fees$17,31848%
- Speaking & faculty fees$5001%
- Travel & lodging$4,49913%
- Food & beverage$13,29837%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 35 | $16,716 |
| Rxsight Inc | 13 | $5,083 |
| Biotissue Holdings Inc. | 49 | $4,055 |
| Nidek CO., LTD. | 1 | $3,300 |
| Tarsus Pharmaceuticals, Inc. | 15 | $2,206 |
| Bausch & Lomb Americas Inc. | 27 | $1,905 |
| Dompe US, Inc. | 51 | $1,244 |
| Mallinckrodt Hospital Products Inc. | 43 | $1,079 |
| Alcon | 14 | $733 |
| Sight Sciences, Inc. | 6 | $631 |
| AbbVie(2 entities) | 12 | $400 |
| NEW World Medical,inc. | 3 | $261 |
| Oyster Point Pharma, Inc. | 12 | $204 |
| Novartis | 7 | $193 |
| Harrow Eye, LLC | 9 | $173 |
| Kala Pharmaceuticals, Inc. | 6 | $148 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $146 |
| Rayner Intraocular Lenses Limited | 1 | $125 |
| Genentech USA, Inc. | 1 | $117 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $98 |
| Amgen | 4 | $68 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Sun Pharmaceutical Industries Inc. | 2 | $35 |
| Halozyme Inc | 1 | $26 |
| Alimera Sciences, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$7,188
- RXSIGHT INJECTOR HANDPIECE$4,997
- RXSIGHT CONTACT LENS$4,997
- LIGHT ADJUSTABLE LENS (LAL)$4,997
- RXSIGHT INJECTOR CARTRIDGE$4,997
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,997
- iStent inject W$2,878
- Travoprost Intraocular Implant - iDose$2,575
- enVista MX60 IOL$1,871
- CE-marked KXLA system$1,380
- Prokera$994
- AmnioGraft$994
- Photrexa$671
- iStent Trabecular Micro-Bypass Stent System$625
- KXL System$539
- Oxervate$527
- iStent inject Trabecular Micro-Bypass Stent System$515
- enVista Aspire IOL$506
- OMNI(R) SURGICAL SYSTEM (US)$429
- SION SURGICAL INSTRUMENT$288
How this compares
$39,015 in reported general payments places this provider in the 85th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 64 | $2,749,068 |
| XiidraLifitegrast | 126 | $149,976 |
| RestasisCyclosporine | 50 | $46,271 |
| XdemvyLotilaner | 22 | $39,668 |
| Cyclosporine | 21 | $20,949 |
| Prednisolone Acetate | 615 | $20,209 |
| TyrvayaVarenicline Tartrate | 19 | $12,053 |
| MoxifloxacinMoxifloxacin Hcl | 400 | $10,559 |
| Loteprednol Etabonate | 23 | $4,499 |
| ValacyclovirValacyclovir Hcl | 32 | $2,023 |
| Brimonidine Tartrate | 29 | $864 |
| Ketorolac Tromethamine | 35 | $858 |
| ErythromycinErythromycin Base | 32 | $321 |
| Timolol Maleate | 26 | $278 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $1,244 | $2,749,06864 claims |
| Bausch & Lomb Americas Inc.Xiidra | $1,905 | $149,976126 claims |
| AbbVieRestasis | $400 | $46,27150 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,206 | $39,66822 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $204 | $12,05319 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $98 | $4,49923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Brookline
- Mark HughesBrookline$145K
- Jason BrennerBrookline$52K
- Gail TorkildsenAndover$5.1M
- David LallySpringfield$4.5M
- Jennifer SunBoston$4.2M
- Lloyd AielloBoston$3.1M
- Rishi SinghBoston$2.5M
- Rachel HuckfeldtStoneham$1.7M
- Mark AbelsonAndover$1.3M
- Peter ChangWaltham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.